Amendment of regulation 279 (products without a marketing authorisation)U.K.
[F1211. For regulation 279 substitute—
“279.—(1) A person may not publish an advertisement in Great Britain for a medicinal product unless one of the following is in force for the product—
(a)a UKMA(GB) or UKMA(UK);
(b)a COR(GB) or COR(UK); or
(c)a THR(GB) or THR(UK).
(2) A person may not publish an advertisement in Northern Ireland for a medicinal product unless one of the following is in force for the product—
(a)a UKMA(NI) or UKMA(UK);
(b)a COR(NI) or COR(UK);
(c)a THR(NI) or THR(UK);
(d)an EU marketing authorisation; or
(e)an Article 126a authorisation.
(3) A person may not publish an advertisement in the whole United Kingdom for a medicinal product unless, in relation to that product—
(a)one of the authorisations or registrations specified in paragraph (1) is in force in Great Britain; and
(b)one of the authorisations or registrations specified in paragraph (2) is in force in Northern Ireland.”.]
Textual Amendments
F1Reg. 211 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 167
Commencement Information
I1Reg. 211 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1